Brief: Celyad Announces Q3 Financial Results And Recent Business Highlights
19/11/2019 07:37
Nov 19 (Reuters) - CELYAD SA CYAD.BR :
* CELYAD ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND
RECENT
BUSINESS HIGHLIGHTS
* COMPLETED ENROLLMENT IN DOSE-ESCALATION SEGMENT OF
ALLOSHRINK
TRIAL WITH ADDITIONAL RESULTS FROM TRIAL ANTICIPATED DURING
FIRST HALF 2020
* CONTINUED ADVANCEMENT OF PROPRIETARY NON-GENE EDITED
ALLOGENEIC
SHORT HAIRPIN RNA (SHRNA) PLATFORM RELATED TO CYAD-200 SERIES OF
SHRNA-BASED ALLOGENEIC CAR-T CANDIDATES
* CLOSED GLOBAL EQUITY OFFERING WITH GROSS PROCEEDS OF $20.0
MILLION (APPROXIMATELY EUR 18.2 MILLION) IN SEPTEMBER 2019
* SUCCESSFULLY DOSED FIRST RELAPSED/REFRACTORY (R/R) ACUTE
MYELOID
LEUKEMIA (AML) PATIENT IN DEPLETHINK PHASE 1 TRIAL WITH CYAD-01
PRODUCED WITH OPTIMAB MANUFACTURING PROCESS
Source text for Eikon: ID:nBwblJ8JGa
Further company coverage: CYAD.BR
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com;))